Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENDRA Life Sciences Inc.NDRA · Entity 8083 | Director | January 21, 2026 | January 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENDRA Life Sciences Inc.
Report date January 21, 2026 · Filed January 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,710 |
Reported balance
After 2026-01-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 60,324 · Balance 65,710 F1: Holdings include unvested restricted stock units ("RSUs"). F2: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include unvested restricted stock units ("RSUs").
F2: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Compute Health Acquisition Corp.
Report date August 01, 2023 · Filed August 03, 2023
Section 16 reporting ended · disclosed 2023-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-08-01 · Grant · Acquired 21,120 · Balance 31,120 F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F2: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. Row 2 · 2023-08-01 · Disposition to issuer · Disposed 31,120 · Balance 0 F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F2: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. F3: Pursuant to the terms of the Business Combination Agreement, each share of Class A Common Stock was canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date. F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F2: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 0 |
Reported balance
After 2023-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-01 · Disposition to issuer · Disposed 2,500 · Balance 0 F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F5: Pursuant to the terms of that certain First Amendment to the Warrant Agreement, dated as of August 1, 2023, by and between the issuer and Continental Stock Transfer & Trust Company ("CST") and that certain Warrant Assignment, Assumption and Amendment Agreement, dated as of August 1, 2023, by and between the issuer and CST, each then-outstanding issuer public warrant acquired from the issuer was assumed by Pubco and converted into 0.6125 warrants to purchase 1.420455 shares of Pubco at an exercise price of $8.10 per whole share. F6: These warrants become exercisable 30 days after the completion of the Business Combination and expire seven years after the completion of the Business Combination or earlier upon redemption or liquidation. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").
F2: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.
F3: Pursuant to the terms of the Business Combination Agreement, each share of Class A Common Stock was canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value.
F4: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date.
F5: Pursuant to the terms of that certain First Amendment to the Warrant Agreement, dated as of August 1, 2023, by and between the issuer and Continental Stock Transfer & Trust Company ("CST") and that certain Warrant Assignment, Assumption and Amendment Agreement, dated as of August 1, 2023, by and between the issuer and CST, each then-outstanding issuer public warrant acquired from the issuer was assumed by Pubco and converted into 0.6125 warrants to purchase 1.420455 shares of Pubco at an exercise price of $8.10 per whole share.
F6: These warrants become exercisable 30 days after the completion of the Business Combination and expire seven years after the completion of the Business Combination or earlier upon redemption or liquidation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2026 Filed Jan 24, 2026 00:43 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 60,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-021414 · ownership.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,710 F1 · security: Holdings include unvested restricted stock units ("RSUs"). F2 · shares: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2026. Read SEC document |
| June 11, 2025 Filed Jul 1, 2025 10:25 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 5,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-091887 · ownership.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,386 F1 · shares: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026. Read SEC document |
| January 02, 2024 Filed Feb 23, 2024 22:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 600 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-24-003900 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2034-01-02 F1 · shares: Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:39 UTC | Compute Health Acquisition Corp. CPUH · Entity 110906 | Disposition to issuerWarrants · Derivative | 2,500 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001209191-23-044454 · doc4.xml · derivative · entry 4 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,500 shares Expires not disclosed F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F5 · kind: Pursuant to the terms of that certain First Amendment to the Warrant Agreement, dated as of August 1, 2023, by and between the issuer and Continental Stock Transfer & Trust Company ("CST") and that certain Warrant Assignment, Assumption and Amendment Agreement, dated as of August 1, 2023, by and between the issuer and CST, each then-outstanding issuer public warrant acquired from the issuer was assumed by Pubco and converted into 0.6125 warrants to purchase 1.420455 shares of Pubco at an exercise price of $8.10 per whole share. F5 · price: Pursuant to the terms of that certain First Amendment to the Warrant Agreement, dated as of August 1, 2023, by and between the issuer and Continental Stock Transfer & Trust Company ("CST") and that certain Warrant Assignment, Assumption and Amendment Agreement, dated as of August 1, 2023, by and between the issuer and CST, each then-outstanding issuer public warrant acquired from the issuer was assumed by Pubco and converted into 0.6125 warrants to purchase 1.420455 shares of Pubco at an exercise price of $8.10 per whole share. F6 · derivative.exercise_date: These warrants become exercisable 30 days after the completion of the Business Combination and expire seven years after the completion of the Business Combination or earlier upon redemption or liquidation. F6 · derivative.expiration_date: These warrants become exercisable 30 days after the completion of the Business Combination and expire seven years after the completion of the Business Combination or earlier upon redemption or liquidation. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:39 UTC | Compute Health Acquisition Corp. CPUH · Entity 110906 | Disposition to issuerClass B Common Stock · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044454 · doc4.xml · derivative · entry 3 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed F4 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date. F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F2 · kind: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. F2 · price: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. F4 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date. F4 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:39 UTC | Compute Health Acquisition Corp. CPUH · Entity 110906 | Disposition to issuerClass A Common Stock | 31,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044454 · doc4.xml · nonDerivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F2 · kind: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. F3 · price: Pursuant to the terms of the Business Combination Agreement, each share of Class A Common Stock was canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:39 UTC | Compute Health Acquisition Corp. CPUH · Entity 110906 | GrantClass A Common Stock | 21,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044454 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,120 F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F2 · kind: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. F2 · price: Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 01:30 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 9,634 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001209191-23-006050 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,634 Underlying: Common Stock · 9,634 shares Expires 2033-01-30 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 21:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 109,492 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-021619 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,492 Underlying: Common Stock · 109,492 shares Expires 2032-03-28 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 22:05 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-22-000954 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-03 F1 · shares: Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:16 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025861 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| January 04, 2021 Filed Mar 25, 2021 21:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-21-023040 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-04 F1 · shares: Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 12:23 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | OtherWarrants · Derivative | 5,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-20-038682 · doc4.xml · derivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,056 Underlying: Common Stock · 5,000 shares Expires 2024-12-11 Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 12:23 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | OtherCommon Stock | 5,000 | $0.87 | $4,350.00 |
DisclosureSEC source: 0001209191-20-038682 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,243 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:39 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionSeries A Convertible Preferred Stock · Derivative | 9.618 | $1,143.68 Strike: $0.87 | $10,999.91 |
DisclosureSEC source: 0001209191-20-035439 · doc4.xml · derivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A Convertible Preferred Stock has no expiration date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:39 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionCommon Stock | 11,386 | $0.87 | $9,905.82 |
DisclosureSEC source: 0001209191-20-035439 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:45 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 42,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024216 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,857 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:22 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-20-001796 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:49 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantWarrants · Derivative | 11,056 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-19-060087 · doc4.xml · derivative · entry 3 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,056 Underlying: Common Stock · 11,056 shares Expires 2024-12-11 F4 · price: The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:49 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantSeries A Convertible Preferred Stock · Derivative | 9.618 | $1,143.68 Strike: $0.87 | $10,999.91 |
DisclosureSEC source: 0001209191-19-060087 · doc4.xml · derivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9.618 Underlying: Common Stock · 11,056 shares Expires not disclosed F2 · derivative.exercise_price: The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A preferred stock has no expiration date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:49 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock option (right to buy) · Derivative | 89,922 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060087 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,922 Underlying: Common Stock · 89,922 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| June 10, 2019 Filed Jun 14, 2019 21:39 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 500 | $1.14 | $570.00 |
DisclosureSEC source: 0001209191-19-037236 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.11 to $1.16, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 20:26 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 2,800 | $1.12 | $3,136.00 |
DisclosureSEC source: 0001209191-19-035800 · doc4.xml · nonDerivative · entry 3 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:26 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 6,600 | $1.11 | $7,326.00 |
DisclosureSEC source: 0001209191-19-035800 · doc4.xml · nonDerivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.16, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 05, 2019 Filed Jun 10, 2019 20:26 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 100 | $1.20 | $120.00 |
DisclosureSEC source: 0001209191-19-035800 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:03 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-19-021511 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-03-25 F1 · shares: Represents a stock option award granted on March 25, 2019 pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 25, 2020. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:27 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,061 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001654954-18-000113 · section16.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,061 Underlying: Common Stock · 6,061 shares Expires 2026-01-02 F1 · shares: Represents a stock option award granted on January 2, 2018 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 12, 2017 Filed May 17, 2017 01:17 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-032900 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2022-05-12 Read SEC document |
| May 12, 2017 Filed May 23, 2017 22:07 UTC Amendment | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034739 · doc4a.xml · derivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-05-12 F2 · derivative.exercise_date: This amendment is being filed to correct the exercisable date of these Stock Options, which was inadvertantly reported as May 12, 2017. The correct exercisable date is December 31, 2017. F1 · derivative.expiration_date: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025. Read SEC document |
| May 12, 2017 Filed May 23, 2017 22:07 UTC Amendment | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034739 · doc4a.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-05-12 F1 · derivative.expiration_date: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.